£33 million joint investment to boost skills, support jobs and bolster green manufacturing in UK life sciences industry
Business / Sun 6th Aug 2023 at 10:05am
£33 million of joint government and industry investment with leading global firm Kindeva Drug Delivery in UK medicines manufacturing will ensure a new generation of green, low-carbon, respiratory inhalers are made in the UK, supporting efforts to grow the economy.
The investment will create 40 full-time jobs and safeguard 218 existing full-time jobs across Kindeva’s sites in Clitheroe and Loughborough.
This is the sixth investment delivered through the Life Sciences Innovative Manufacturing Fund (LSIMF), which has supported UK life sciences manufacturing with £340 million in joint government and industry backing in the last financial year, and £416 million since 2021. Through this ongoing work, the government is helping the UK’s thriving life sciences sector to grow our economy and create well-paid jobs across the country – one of the Prime Minister’s five priorities.
Today’s funding comes from the Chancellor’s £650 million ‘Life Sci for Growth’ war-chest, announced in May this year, to fire up the UK’s life sciences sector and helps to deliver the Science and Technology framework through reforming regulation, boosting investment and driving up talent and skills.
LSIMF follows on from the Medicines and Diagnostics Manufacturing Transformation Fund (MDMTF) pilot programme which launched in April 2021. Over its lifespan, MDMTF delivered £75 million in joint government and industry investment, while also creating 224 new jobs and protecting 345 existing roles.
Kindeva Drug Delivery is a leading global contract development and manufacturing organization (“CDMO”) specializing in pharmaceutical drug-device combination products, such as inhalers, nebulizers and medicated patches.
The government’s Life Sciences Vision, published in 2021, set the ambition to create a globally competitive environment for Life Science manufacturing investments, building on the strengths of our manufacturing R&D, our network of innovation centres, the manufacturing response to COVID-19 and delivery of the Medicines and Diagnostics Manufacturing Transformation Fund. Life sciences are also central to the UK Science and Technology Framework, which identifies the critical technologies set to make the biggest difference to health and life science progress, as well as plans to improve the regulatory landscape for life sciences.
A good bit of PR for our Tory government, but an investment in Clitheroe and Loughborough is not much use for people in Harlow with the nearest place being 118 miles away according to Google Maps. Perhaps this is to compensate for failing to bring Public Health England to Harlow?
Dave, ref: only fools and horses. PHE, then as now no longer exist..
For Bruce Downey's benefit I am well aware that PHE was reorganised and renamed as two new entities: UK Health Security Agency and the Office for Health Improvement and Disparities. However, people will remember Halfon pledging to bring Public Health England to Harlow and failing miserably to deliver.